Free tools Windows power users keep installed
One-click scans. No signup required.
Stopping semaglutide commonly leads to some weight regain, and improvements in cardiometabolic measures may move back toward a person’s previous levels. In the STEP 1 withdrawal extension, adults without diabetes who had used weekly semaglutide 2.4 mg for 68 weeks regained an average of about two-thirds of the weight they had lost during the following year without treatment.
That result is a study average, not an individual forecast. The trial involved Wegovy-dose semaglutide for obesity in people without diabetes; it did not directly test what happens to blood glucose when a person with type 2 diabetes stops Ozempic. Anyone considering a change should make a monitoring and treatment plan with the prescribing clinician.
As an Amazon Associate I earn from qualifying purchases.
The short answer
Weight regain after stopping semaglutide is common, but the amount and timing differ from person to person. Some people retain part of their loss, while others regain most of it. In the STEP 1 extension, average weight remained below the original starting point one year after withdrawal, yet most of the medication-associated loss had returned.
Stopping can also affect health measures linked with weight. The trial reported that improvements in several cardiometabolic measurements moved toward baseline by the end of follow-up. That does not mean every measure returned completely to its starting value or that every participant followed the group average.
#1 Best Overall
- 𝑹𝒆𝒍𝒊𝒂𝒃𝒍𝒆 𝑷𝒓𝒆𝒄𝒊𝒔𝒊𝒐𝒏: With professional expertise refined over 10 years, our brand design ensures accuracy and reliability through high-precision sensor technology
- 𝑬𝒂𝒔𝒚 𝒕𝒐 𝑼𝒔𝒆: The scale is equipped with an easy-to-read display with automatic on/off, low battery, and overload indications. Choose between 2 units of measurement (lb/kg) for your weighing convenience
- 𝑴𝒊𝒏𝒊𝒎𝒂𝒍 𝑫𝒆𝒔𝒊𝒈𝒏: Never Let a scale ruin your style. Place this scale in your bathroom, bedroom, or living room. It will complement the design of your living space
- 𝑨 𝑫𝒖𝒓𝒂𝒃𝒍𝒆 𝑪𝒉𝒐𝒊𝒄𝒆: The scale’s 6-mm tempered glass platform provides exceptional durability and comfort. Equipped with a supportive frame and anti-skid paddings to prevent slipping, you can rely on the sturdiness of our scale
- 𝑳𝒂𝒓𝒈𝒆 𝑷𝒍𝒂𝒕𝒇𝒐𝒓𝒎: Step onto the scale comfortably with its large 11.9 x 11.9-inch platform
Ozempic and Wegovy both contain semaglutide, but they are used in different treatment contexts. Evidence from a Wegovy-dose obesity study should not be presented as a precise prediction for a person taking Ozempic for type 2 diabetes.
What the STEP 1 extension actually measured
The most informative withdrawal data come from the exploratory extension of STEP 1, reported by Wilding and colleagues in 2022. The original randomized trial enrolled 1,961 adults with obesity, or with overweight plus at least one weight-related condition, who did not have diabetes. Participants received weekly subcutaneous semaglutide 2.4 mg or placebo, together with a structured lifestyle intervention, for 68 weeks. Only 327 participants were included in the subsequent extension analysis.
For the extension, both the study medication and the structured lifestyle intervention were stopped. Participants were followed to week 120, approximately one year after the 68-week treatment period. The design therefore shows what happened after this particular treatment-and-support program ended; it does not isolate medication withdrawal from the loss of structured lifestyle support.
Recommended Free Tools
| Measure | Former semaglutide group | Former placebo group |
|---|---|---|
| Mean weight change through week 68 | 17.3% loss from baseline | 2.0% loss from baseline |
| Change from the week-68 weight by week 120 | Regained 11.6 percentage points of the weight previously lost | Regained 1.9 percentage points of the weight previously lost |
| Mean weight relative to original baseline at week 120 | 5.6% below baseline | 0.1% below baseline |
The authors summarized the semaglutide group as having regained about two-thirds of its prior weight loss within the year after withdrawal. “Two-thirds” describes the average proportion across the analyzed group; it is not a schedule or a guaranteed amount for an individual.
Rank #2
- 𝗨𝗻𝗺𝗮𝘁𝗰𝗵𝗲𝗱 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻: With 10 years of expertise, we’re trusted by over 5 million customers in 30+ countries. we take pride in our high-precision sensors—the core tech that's responsible for the accuracy in increments down to 0.05 lb
- 𝗪𝗲𝗶𝗴𝗵𝘁 𝗩𝗲𝗿𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗗𝗼𝘂𝗯𝗹𝗲 𝗖𝗵𝗲𝗰𝗸 𝗧𝗲𝗰𝗵: Experience unmatched convenience and accuracy. Simply step on, and the scale quickly checks and ensures precise results—no need to tap or wait for the display to show zero
- 𝗠𝗲𝗮𝘀𝘂𝗿𝗲 𝗟𝗶𝗴𝗵𝘁 𝗜𝘁𝗲𝗺𝘀: Such a versatile scale. Not only can measure your body weight, but also easily weigh items as light as 100g like pets and their food with pinpoint accuracy
- 𝗘𝗮𝘀𝘆 𝘁𝗼 𝗥𝗲𝗮𝗱: Best choice for the elderly. The extra-bright LED display with large and clear numbers make it easy to read for all especially for the seniors, no need bending over or wearing presbyopic glasses
- 𝗨𝘁𝗺𝗼𝘀𝘁 𝗦𝗮𝗳𝗲 𝗮𝗻𝗱 𝗔𝗲𝘀𝘁𝗵𝗲𝘁𝗶𝗰: Expertly designed in California, our stylish scale fits seamlessly in your bedroom/bathroom/home. The sleek round corners, large anti-skid padding, and full-coverage bottom ensure durability and stability
The extension was exploratory and analyzed a subset of the original participants. Its population, dose, duration and lack of diabetes limit how broadly the findings can be applied. The full publication is available in the STEP 1 trial extension record.
How weight change can unfold after the last dose
During treatment
By week 68, the semaglutide group had lost an average of 17.3% of baseline weight in STEP 1, compared with 2.0% in the placebo group. That difference reflects the treatment period, when participants also received structured lifestyle support. It is the starting point for understanding the later withdrawal results.
During the following year
By week 120, the former semaglutide participants had regained an average of 11.6 percentage points of their earlier loss. Because they had lost 17.3% on average by week 68, the group still averaged 5.6% below its original baseline. The former placebo group averaged 0.1% below baseline at the same time.
Why an individual timeline cannot be predicted
The study reports group means rather than a fixed pattern such as a specific number of pounds per month. It does not establish that regain starts on a particular day, proceeds at a constant rate or reaches the same point for everyone. Starting weight, treatment response, medical conditions, other medicines, eating patterns, activity and the availability of follow-up can all differ, but STEP 1 was not designed to calculate an individualized forecast for those factors.
Rank #3
- ⚖️ 10-Year Accuracy with 4 G-Sensors: Equipped with 4 upgraded G-sensors for ±0.1 lb / 0.05 kg precision, this scale uses two long-lasting AAA batteries to provide stable power and consistent readings. Its optimized circuit design has been tested to deliver reliable accuracy for at least 10 years of daily use—ideal for routine morning weigh-ins and long-term tracking. 2*AAA Batteries Included
- 🔁 Quick kg / lb / st Switching for Everyday Tracking: One-button unit switching makes it easy to compare numbers with gym equipment, fitness apps, or medical checkups. Supports 180 kg / 400 lb / 28 st and fits seamlessly into real daily routines—morning weight checks, intermittent fasting logs, weekly fitness tracking, and shared bathroom use
- ⚡ Instant Step-On Results for Busy Mornings & Night Use: Delivers fast, stable measurements the moment you step on—no tapping, no setup. The bright backlit LED display stays clear during early-morning weigh-ins, low-light bathrooms, post-shower checks, and night-time measurements. Auto-calibration ensures consistency across repeated daily use
- 🛡️ Reinforced Safety Design: Constructed with 6 mm tempered glass, rounded corners, a reinforced internal frame, and an anti-slip base, this scale is designed for long-term durability and daily reliability. Ideal for wet bathroom floors after showers, kids stepping on out of curiosity, seniors checking weight daily, and frequent users during weight-loss cycles
- 🧩 Compact 26 cm Footprint—Fits Small Bathrooms & Modern Spaces: At 10.2 × 10.2 × 0.87 in, this slim digital scale fits under cabinets, next to toilets, in small apartments, dorm bathrooms, home gyms, or bedside wellness setups. The smooth tempered-glass surface wipes clean easily—great for users who weigh in daily, track fitness progress, or maintain long-term health routines
Why Ozempic and Wegovy should not be treated as interchangeable evidence
Both products contain semaglutide, but the labeled purposes and dosing contexts differ. FDA review material describes Wegovy in the chronic weight-management setting and Ozempic at marketed doses for improving glycemic control in adults with type 2 diabetes. Current prescribing information should be checked before making a treatment change; the FDA review material is available at FDA.gov.
| Question | What the available evidence supports | What it does not establish |
|---|---|---|
| What was withdrawn in STEP 1? | Weekly semaglutide 2.4 mg used for 68 weeks in adults without diabetes, followed by one year without the study drug or structured lifestyle program. | A direct discontinuation study of every Wegovy user, every semaglutide dose or every treatment duration. |
| What does this say about Ozempic? | It confirms that semaglutide withdrawal in a specific obesity trial was followed by substantial average weight recurrence. | An exact weight or blood-glucose prediction for a person using Ozempic for type 2 diabetes. |
| What should a person with diabetes plan? | A clinician-guided glucose-monitoring and diabetes-treatment plan before any change. | A universal glucose outcome after stopping, because the cited withdrawal trial excluded people with diabetes. |
If Ozempic is being used for type 2 diabetes, the immediate concern is not only weight. Stopping may require changes to glucose monitoring and to other or ongoing diabetes treatment. The cited sources do not provide an individualized prediction of how a particular person’s blood glucose will respond.
What may happen to cardiometabolic improvements
Weight is only one outcome. In the STEP 1 extension, improvements in most measured cardiometabolic variables moved toward baseline by week 120. This means the favorable changes seen during treatment were less pronounced after withdrawal on average.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
The wording matters: “moved toward baseline” is not the same as “all benefits disappeared.” The extension did not show that every participant lost every improvement, and it was not powered to provide an individual risk forecast. A person’s blood pressure, lipids, glucose and other measures need to be interpreted using their own clinical history and follow-up tests.
Rank #4
- Professional Accuracy: With 15 years experience, 20,000+ times reliablility test and advanced patented SaluOptim Tech, this weight scale ensures exceptional precision for your health and fitness
- Optimal Size & Easy-to-Read: With 11.8*11.8 inch platform, you can stand comfortably on your bath scale(Maximum capacity 450lb/205kg). Besides, sleek design, the bright, large LED digital display enables easy reading
- Safe and Durable: Designed with full-coverage base and 6mm tempered glass, the scale is sturdy and durable which is safe for the elderly and children. Also, the 4*AAA batteries included can long last for 18 months
- Special Features: Swithed to Family Mode, the weight of your baby/pet can be calculated automatically by patented Famicare Tech. Besides, light items under 22lb such as packages or pet foods can be measured precisely with the increment down to 0.05lb
- Meet High Standards: The Ovutek scale stands up to the highest standards for everyday users. We genuinely hope to leave you amazed and provide an unforgettable experience
For someone with type 2 diabetes, blood-glucose management has an additional safety dimension. The STEP 1 population did not have diabetes, so its results cannot supply a post-Ozempic glucose number or tell a patient whether another diabetes medicine will be needed.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What current guidance says about long-term treatment
The American Diabetes Association’s Standards of Care in Diabetes—2026 describes obesity as a chronic, relapsing disease and notes that stopping chronic obesity medication often results in weight recurrence and worsening or reemergence of cardiometabolic risks. The document supports shared decision-making about continuing treatment at an individualized effective dose or stopping with close weight monitoring. Read the guidance at the ADA Standards of Care in Diabetes—2026.
“Obesity is a chronic, relapsing disease, similar to hypertension, and typically requires continuation of pharmacotherapy after weight reduction goals are achieved to sustain weight loss and health benefits.”
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.American Diabetes Association, Standards of Care in Diabetes—2026
Best Value
Vitafit Bathroom Scale for Body Weight Accuracy 0.1lb, Weight Scale 400lb
- DURABLE ACCURACY CHOICE - Our owned professional factory has been focusing on high quality scales SINCE 2001, we make the digital scale for body weight with best-in-class technology and expertise, and proudly guarantee capacity 400lb/182kg in high 0.1lb/0.05kg division throughout the bathroom scale lifecycle. It helps you to stay fit and monitor your health.
- EASY TO USE - The weight scale is utilized up-to-date digital technology, along with many friendly features, including: auto calibration, auto step-on, auto power off, comfortable platform in 10.9'' x 10.9'', 3*AAA batteries included, 3 units switch: lb/kg/st. Easy for healthy progress or weight loss.
- EASILY VISIBLE LED - The digital scales for body weight are equipped with crystal clear LED in large number size, specially designed for clearly viewing numbers in any conditions, and kept the same brightness throughout batteries' lifecycle.
- EASILY VISIBLE LED - The digital scales for body weight are equipped with crystal clear LED in large number size, specially designed for clearly viewing numbers in any conditions, and kept the same brightness throughout batteries' lifecycle. Whether bodybuilding or just daily fitness, our scale supports your goals.
- BEYOND OUR DIGITAL SCALE - Based on over 20 years focusing on scales, our professional scales digital weight factory has been certified by ISO and Social Accountability for quality and social responsibility. All Vitafit Scale proudly developed and produced by ourselves. All Vitafit products are supported by our US customer service center in the heartland state Missouri. Vitafit: Inspired by Life, for Better Life.
This is guidance for a chronic condition, not an instruction that every person must remain on a medicine indefinitely. The appropriate choice depends on the treatment goal, benefits, side effects, access, cost, other conditions and the person’s preferences. If stopping is chosen, the ADA emphasizes close monitoring rather than assuming that the result will remain stable without follow-up.
The ADA also identifies regular physical activity, self-monitoring and a nutrient-dense eating pattern as strategies reported by successful long-term weight-loss maintainers. It explicitly notes that these strategies have not been validated specifically for preventing regain after GLP-1 therapy. They should therefore not be advertised as a proven post-semaglutide replacement protocol.
How to plan a medically supervised stop
A prescriber can help decide whether stopping, continuing or changing treatment best fits the reason the medicine was prescribed. A practical discussion can follow this sequence:
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minute- Define the treatment goal. Clarify whether the medicine is being used primarily for chronic weight management, glucose lowering in type 2 diabetes, or both. The goal determines which outcomes must be monitored.
- Review the current product and dose. Confirm whether the prescription is Ozempic, Wegovy or another semaglutide product, the current dose, the duration of use and the latest official labeling. Product indications and dosing should not be inferred from the STEP 1 withdrawal dose.
- Discuss the alternatives. Shared decision-making can include continuing at an individualized effective dose, changing treatment, or stopping. Compare expected benefit, tolerability, treatment burden, cost or access and the monitoring required for each option.
- Set a weight-monitoring method. If the clinician recommends it, a home scale can help reveal a trend. It is an optional monitoring aid, not a treatment for regain and not a substitute for clinical review. Agree on how often to record measurements and what change should prompt contact.
- Create a glucose plan when relevant. A person with diabetes should know when to check blood glucose, which readings require a call and how other diabetes medicines will be continued or adjusted. The prescriber should provide the individualized instructions.
- Schedule follow-up. Arrange clinical review after the change so weight, glucose when relevant and other cardiometabolic measures can be assessed. Do not rely on the STEP 1 average to decide that a personal result is acceptable or expected.
What has not been proven to prevent regain
The cited guidance and withdrawal trial do not establish a universal tapering schedule, a specific diet, a particular exercise prescription or a guaranteed medication switch that prevents weight recurrence after semaglutide cessation. The study stopped treatment and structured lifestyle support together, so it cannot identify a single intervention that would have preserved the treatment-period loss.
That evidence gap does not mean lifestyle care is irrelevant. It means a clinician should avoid promising that one plan will reliably reproduce the medication’s effect after stopping. Any nutrition, activity or behavioral strategy should be individualized, feasible and monitored as part of ongoing care rather than presented as a validated antidote to withdrawal-related regain.
Questions to settle before changing treatment
- What condition is the semaglutide treating, and which outcome matters most: weight, blood glucose, or both?
- What amount of regain or change in another measurement should trigger a follow-up?
- For diabetes, which glucose readings require urgent advice and what medicines continue during the transition?
- Would continuing treatment at an individualized effective dose provide benefits that outweigh burden, side effects, cost and access concerns?
- Which current prescribing details need to be checked before the next dose or a replacement treatment?
The STEP 1 extension shows why follow-up matters: after a strong average response during treatment, substantial average regain occurred during the next year without semaglutide. The ADA’s current approach is to make that decision jointly with a clinician and to monitor closely if stopping is selected.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
